Dll4 Inhibition plus Aflibercept markedly reduces ovarian tumor growth

Molecular Cancer Therapeutics

Volumn 15, Issue 6, 2016, Pages 1344-1352

  Huang, Jie ^a   Hu, Wei ^a   Hu, Limin ^b   Previs, Rebecca A ^a   Dalton, Heather J ^a   Yang, Xiao Yun ^a   Sun, Yunjie ^a   McGuire, Michael ^a   Rupaimoole, Rajesha ^a   Nagaraja, Archana S ^a   Kang, Yu ^a,c   Liu, Tao ^a,d   Nick, Alpa M ^a   Jennings, Nicholas B ^a   Coleman, Robert L ^a   Jaffe, Robert B ^b   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FUDAN UNIVERSITY   (China)

^d UNION HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; CASPASE 3; DELTA LIKE LIGAND 4; DELTA LIKE LIGAND 4 FC; DOCETAXEL; FRACTALKINE; KI 67 ANTIGEN; LIGAND; REGN 1035; REGN 421; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; GATA3 PROTEIN, MOUSE; HYBRID PROTEIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PROTEIN; REGN421; SIGNAL PEPTIDE; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; CANCER INHIBITION; CAPILLARY DENSITY; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; ANIMAL; CANCER TRANSPLANTATION; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM; OVARIAN NEOPLASMS; TUMOR CELL LINE; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971505128     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0144     Document Type: Article

References (27)

1. Folkman J.Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005;11:6966-71.
3. Coleman RL, Duska LR, Ramirez PT, Heymach JV, Kamat AA, Modesitt SC, et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 2011; 12:1109-17.
4. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40.
5. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
6. Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001;20:79-86.
7. Thanapprapasr D, Hu W, Sood AK, Coleman RL. Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer. Curr Pharm Des 2012; 18:2713-9.
8. Thurston G, Noguera-Troise I, Yancopoulos GD. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 2007;7:327-31.
9. Hayashi H, Kume T. Foxc transcription factors directly regulate Dll4 and Hey2 expression by interacting with the VEGF-Notch signaling pathways in endothelial cells. PLoS One 2008;3:e2401.
10. Jakobsson L, Bentley K, Gerhardt H. VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem Soc Trans 2009;37: 1233-6.
11. Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006;107:931-9.
12. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032-7.
13. Li JL, Harris AL. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci 2009;14:3094-110.
14. Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, et al. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res 2011;71:6030-9.
15. Kuhnert F, Chen G, Coetzee S, Thambi N, Hickey C, Shan J, et al. Dll4 blockade in stromal cells mediates antitumor effects in preclinical models of ovarian cancer. Cancer Res 2015;75: 4086-96.
16. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9:5721-8.
17. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444:1083-7.
18. Yan W, Cao QJ, Arenas RB, Bentley B, Shao R. GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition. J Biol Chem 2010;285:14042-51.
19. Chu IM, Lai WC, Aprelikova O, El Touny LH, Kouros-Mehr H, Green JE. Expression of GATA3 in MDA-MB-231 triple-negative breast cancer cells induces a growth inhibitory response to TGFss. PLoS One 2013;8:e61125.
20. Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol 2013;15:201-13.
21. Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li JL, et al. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer 2009;101:1749-57.
22. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL. Upregulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 2005; 65:8690-7.
23. Thurston G, Kitajewski J. VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br J Cancer 2008;99:1204-9.
24. Linda JK, Yamamoto M, Leonard MW, Geogre KM, TING P, Engel JD. Murine and human T-Lymphocyte GATA-3 factors mediate transcription through a cis-regulatory element within the human T-Cell receptor 8 gene enhancer. Mol Cell Biol 1991;11:2778-2784.
25. Samson SI, Richard O, Tavian M, Ranson T, Vosshenrich CA, Colucci F, et al. GATA-3 promotes maturation, IFN-gamma production, and liver-specific homing of NK cells. Immunity 2003;19:701-11.
26. Park MH, Lee JS, Yoon JH. High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J Surg Oncol 2012;106:386-92.
27. JimenoA.P. StrotherR.M. DiamondJ.R. PlatoL. YoungerA. MessersmithW.A. et alPhase I study of REGN421 (R)/SAR153192, a fully-human deltalike ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumorsJ Clin Oncol 312013suppl; abstr 2502